Therapeutics targeting angiogenesis: Genetics and epigenetics, extracellular miRNAs and signaling networks (Review)

Carmeliet, 2005, Angiogenesis in life, disease and medicine, Nature, 438, 932, 10.1038/nature04478

Ferrara, 2005, Angiogenesis as a therapeutic target, Nature, 438, 967, 10.1038/nature04483

Folkman, 2007, Angiogenesis: an organizing principle for drug discovery?, Nat Rev Drug Discov, 6, 273, 10.1038/nrd2115

Carmeliet, 2011, Molecular mechanisms and clinical applications of angiogenesis, Nature, 473, 298, 10.1038/nature10144

Gaengel, 2009, Endothelial-mural cell signaling in vascular development and angiogenesis, Arterioscler Thromb Vasc Biol, 29, 630, 10.1161/ATVBAHA.107.161521

Coultas, 2005, Endothelial cells and VEGF in vascular development, Nature, 438, 937, 10.1038/nature04479

Olsson, 2006, VEGF receptor signalling-in control of vascular function, Nat Rev Mol Cell Biol, 7, 359, 10.1038/nrm1911

Presta, 2005, Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis, Cytokine Growth Factor Rev, 16, 159, 10.1016/j.cytogfr.2005.01.004

Fagiani, 2013, Angiopoietins in angiogenesis, Cancer Lett, 328, 18, 10.1016/j.canlet.2012.08.018

Bridges, 2011, Notch regulation of tumor angiogenesis, Future Oncol, 7, 569, 10.2217/fon.11.20

Katoh, 2007, WNT signaling pathway and stem cell signaling network, Clin Cancer Res, 13, 4042, 10.1158/1078-0432.CCR-06-2316

Katoh, 2008, Hedgehog signaling, epithelial-to-mesenchymal transition and miRNA (Review), Int J Mol Med, 22, 271

Rivkin, 2013, The linear ubiquitin-specific deubiquitinase gumby regulates angiogenesis, Nature, 498, 318, 10.1038/nature12296

Diehl, 2012, Neighborhood watch orchestrates liver regeneration, Nat Med, 18, 497, 10.1038/nm.2719

Katoh, 2013, FGF receptors: cancer biology and therapeutics, Med Res Rev

Dewhirst, 2008, Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response, Nat Rev Cancer, 8, 425, 10.1038/nrc2397

Bao, 2012, The biological kinship of hypoxia with CSC and EMT and their relationship with deregulated expression of miRNAs and tumor aggressiveness, Biochim Biophys Acta, 1826, 272

Ferrara, 2005, Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy, Biochem Biophys Res Commun, 333, 328, 10.1016/j.bbrc.2005.05.132

Sandler, 2006, Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell-lung cancer, N Engl J Med, 355, 2542, 10.1056/NEJMoa061884

Schmitt, 2012, Targeting angiogenesis in ovarian cancer, Cancer Treat Rev, 38, 272, 10.1016/j.ctrv.2011.06.004

Hall, 2013, Targeted anti-vascular therapies for ovarian cancer: current evidence, Br J Cancer, 108, 250, 10.1038/bjc.2012.541

Chow, 2007, Sunitinib: from rational design to clinical efficacy, J Clin Oncol, 25, 884, 10.1200/JCO.2006.06.3602

Wilhelm, 2008, Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling, Mol Cancer Ther, 7, 3129, 10.1158/1535-7163.MCT-08-0013

Shojaei, 2012, Anti-angiogenesis therapy in cancer: current challenges and future perspectives, Cancer Lett, 320, 130, 10.1016/j.canlet.2012.03.008

Bertolini, 2011, Anti-VEGF and beyond: shaping a new generation of anti-angiogenic therapies for cancer, Drug Discov Today, 16, 1052, 10.1016/j.drudis.2011.08.007

Konecny, 2013, Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells, Mol Cancer Ther, 12, 632, 10.1158/1535-7163.MCT-12-0999

O’Hare, 2009, AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance, Cancer Cell, 16, 401, 10.1016/j.ccr.2009.09.028

Gavine, 2012, AZD4547: An orally bioavailable, potent and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family, Cancer Res, 72, 2045, 10.1158/0008-5472.CAN-11-3034

Chen, 2009, Adverse effects of anticancer agents that target the VEGF pathway, Nat Rev Clin Oncol, 6, 465, 10.1038/nrclinonc.2009.94

Penn, 2008, Vascular endothelial growth factor in eye disease, Prog Retin Eye Res, 27, 331, 10.1016/j.preteyeres.2008.05.001

Rajagopalan, 2003, Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication, Circulation, 108, 1933, 10.1161/01.CIR.0000093398.16124.29

Roth, 2006, Intracoronary delivery of an adenovirus encoding fibroblast growth factor-4 in myocardial ischemia: effect of serum antibodies and previous exposure to adenovirus, Hum Gene Ther, 17, 230, 10.1089/hum.2006.17.230

Sarkar, 2001, Effects of intramyocardial injection of phVEGF-A165 as sole therapy in patients with refractory coronary artery disease-12-month follow-up: angiogenic gene therapy, J Intern Med, 250, 373, 10.1046/j.1365-2796.2001.00905.x

Belch, 2011, Effect of fibroblast growth factor NV1FGF on amputation and death: a randomised placebo-controlled trial of gene therapy in critical limb ischaemia, Lancet, 377, 1929, 10.1016/S0140-6736(11)60394-2

Formiga, 2012, Angiogenic therapy for cardiac repair based on protein delivery systems, Heart Fail Rev, 17, 449, 10.1007/s10741-011-9285-8

Hoare, 2008, Hydrogels in drug delivery: Progress and challenges, Polymer, 49, 1993, 10.1016/j.polymer.2008.01.027

Aranguren, 2008, Multipotent adult progenitor cells sustain function of ischemic limbs in mice, J Clin Invest, 118, 505

da Meirelles, 2009, Mechanisms involved in the therapeutic properties of mesenchymal stem cells, Cytokine Growth Factor Rev, 20, 419, 10.1016/j.cytogfr.2009.10.002

Suzuki, 2012, Comparative angiogenic activities of induced pluripotent stem cells derived from young and old mice, PLoS One, 7, e39562, 10.1371/journal.pone.0039562

Lichtenstein, 2000, Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland, N Engl J Med, 343, 78, 10.1056/NEJM200007133430201

Zimmet, 2001, Global and societal implications of the diabetes epidemic, Nature, 414, 782, 10.1038/414782a

Eechoute, 2012, Polymorphisms in endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertension, Clin Pharmacol Ther, 92, 503

Scartozzi, 2013, VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib, Br J Cancer, 108, 1126, 10.1038/bjc.2012.501

Petrovič, 2008, Local and genetic determinants of vascular endothelial growth factor expression in advanced proliferative diabetic retinopathy, Mol Vis, 14, 1382

Miles, 2013, Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer, Br J Cancer, 108, 1052, 10.1038/bjc.2013.69

Baylin, 2011, A decade of exploring the cancer epigenome-biological and translational implications, Nat Rev Cancer, 11, 726, 10.1038/nrc3130

Ordovás, 2010, Epigenetics and cardiovascular disease, Nat Rev Cardiol, 7, 510, 10.1038/nrcardio.2010.104

Issa, 2001, Accelerated age-related CpG island methylation in ulcerative colitis, Cancer Res, 61, 3573

Kang, 2003, Aberrant CpG island hypermethylation of chronic gastritis, in relation to aging, gender, intestinal metaplasia, and chronic inflammation, Am J Pathol, 163, 1551, 10.1016/S0002-9440(10)63511-0

Rivenbark, 2012, Field cancerization in mammary carcinogenesis - Implications for prevention and treatment of breast cancer, Exp Mol Pathol, 93, 391, 10.1016/j.yexmp.2012.10.018

Wittmann, 2010, Serum microRNAs as powerful cancer biomarkers, Biochim Biophys Acta, 1806, 200

Kuehbacher, 2008, Targeting microRNA expression to regulate angiogenesis, Trends Pharmacol Sci, 29, 12, 10.1016/j.tips.2007.10.014

Wang, 2009, AngiomiRs - key regulators of angiogenesis, Curr Opin Genet Dev, 19, 205, 10.1016/j.gde.2009.04.002

Gallo, 2012, The majority of microRNAs detectable in serum and saliva is concentrated in exosomes, PLoS One, 7, e30679, 10.1371/journal.pone.0030679

Turchinovich, 2012, Extracellular miRNAs: the mystery of their origin and function, Trends Biochem Sci, 37, 460, 10.1016/j.tibs.2012.08.003

Banigan, 2013, Differential expression of exosomal microRNAs in prefrontal cortices of schizophrenia and bipolar disorder patients, PLoS One, 8, e48814, 10.1371/journal.pone.0048814

Cantaluppi, 2012, Microvesicles derived from endothelial progenitor cells protect the kidney from ischemia-reperfusion injury by microRNA-dependent reprogramming of resident renal cells, Kidney Int, 82, 412, 10.1038/ki.2012.105

Lässer, 2012, Exosomal RNA as biomarkers and the therapeutic potential of exosome vectors, Expert Opin Biol Ther, 12, S189, 10.1517/14712598.2012.680018

Qin, 2013, Early vessel destabilization mediated by Angiopoietin-2 and subsequent vessel maturation via Angiopoietin-1 induce functional neovasculature after ischemia, PLoS One, 8, e61831, 10.1371/journal.pone.0061831